RVTY · News · 20260804N

Acquisition / Partnership / Divestiture

REVVITY, INC. · 2026-08-04 · Importance 65 · Surprise 60 · No source text

Revvity entered a definitive agreement to divest its China Immunodiagnostics business. The business represented approximately 6% of fiscal 2025 revenue, and the transaction is expected to close by the end of 2027. Third-party reporting said the divestiture is expected to improve Revvity's margin profile and capital efficiency while advancing its focus on higher-margin Diagnostics and software.

Key facts

• The divestiture of the China Immunodiagnostics business is expected to close by the end of 2027. source
• Entered a definitive agreement to divest its China Immunodiagnostics business. source
• The China Immunodiagnostics business represented approximately 6% of fiscal year 2025 revenue. source

Impact estimates